# Anika Therapeutics, Inc. (ANIK) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Anika Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/ANIK/mda/fy2025/): filed 2026-03-03; accession 0001171843-26-001275 (https://www.sec.gov/Archives/edgar/data/898437/000117184326001275/anik20251231_10k.htm); latest 10-K
- [FY 2024 MD&A](/company/ANIK/mda/fy2024/): filed 2025-03-17; accession 0001171843-25-001486 (https://www.sec.gov/Archives/edgar/data/898437/000117184325001486/anik20241231_10k.htm)
- [FY 2023 MD&A](/company/ANIK/mda/fy2023/): filed 2024-03-15; accession 0001171843-24-001380 (https://www.sec.gov/Archives/edgar/data/898437/000117184324001380/anik20231231_10k.htm)
- [FY 2022 MD&A](/company/ANIK/mda/fy2022/): filed 2023-03-16; accession 0001171843-23-001729 (https://www.sec.gov/Archives/edgar/data/898437/000117184323001729/anik20221231_10k.htm)
- [FY 2021 MD&A](/company/ANIK/mda/fy2021/): filed 2022-03-11; accession 0001171843-22-001790 (https://www.sec.gov/Archives/edgar/data/898437/000117184322001790/anik20211231_10k.htm)

Back to /company/ANIK/